Reuters
Published Nov 18, 2021 08:09AM ET
Updated Nov 18, 2021 10:40AM ET
By Michael Erman and Julie Steenhuysen
(Reuters) - Johnson & Johnson (NYSE:JNJ) expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company's pharmaceuticals unit on Thursday.
Among the top pipeline assets, Mathai Mammen, global head of research for J&J's Janssen pharmaceutical division, pointed to a drug combination for non-small cell lung cancer, an anticoagulant it is developing with partner Bristol Myers (NYSE:BMY) Squibb and a vaccine for respiratory syncytial virus (RSV).
J&J said last week that it plans to spin off its consumer health division that sells Listerine and Band-Aid bandages in order to focus on pharmaceuticals and medical devices in the biggest shakeup in the U.S. company's 135-year history.
Mammen in an interview said he did not think the transaction would change much in terms of research and development spending.
"We're really happy and proud of the way R&D is functioning - the strategy we're using and the level of investments," he said.
J&J developed one of the three COVID-19 vaccines authorized in the United States, but its use in the country tailed off sharply after rare cases of blood clotting were linked to the shot.
Nonetheless, Mammen said J&J still expects to develop more vaccines using the same adenovirus vector technology.
"It induces not just antibodies that tend to be relatively short-lived, but also good, multiple kinds of T-cells... so you have that really long-lasting benefit," Mammen said.
Mammen said the company was "actively looking" at a lot of different technology platforms, including messenger RNA, the backbone of the COVID-19 vaccines from Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) and partner BioNTech
"We have several technologies right now, and we'll look at expanding that out further," he said.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.